Our study here demonstrated the primary use of biodegradable CA NPs to deliver BRCA1 and BRCA2 plasmids into breast cancer cells and explored the outcome of gene augmentation on tumor regression. The gene discussed is BRCA2; the disease is breast carcinoma.